In clinical trials of TESAVEL as monotherapy and sitagliptin as part of combination therapy with metformin or pioglitazone, rates of hypoglycaemia reported with sitagliptin were similar to rates in patients taking placebo.
TESAVEL´i monoteraapia kliinilistes uuringutes ja sitagliptiini kliinilistes uuringutes osana kombineeritud ravist koos metformiini või pioglitasooniga, oli sitagliptiiniga täheldatud hüpoglükeemia esinemissagedus sarnane platseebot manustanud patsientide omale.